Syngoi has inaugurated its new facilities at the Zamudio/Derio Campus of the Technology Parks
The event was presided over by the Deputy General of Bizkaia, Unai Rementeria Maiz, in the presence of Arantxa Tapia, Minister of Economic Development, Sustainability and Environment of the Basque Government, authorities, entrepreneurs and scientists, among other guests
Syngoi, the first biotechnology company in the world to manufacture synthetic DNA that is optimised and adaptable for advanced therapies, has inaugurated its facilities on the Zamudio/Derio Campus of the Basque Technology Parks.
The event took place in the central auditorium of the Camous and was presided over by the Deputy General of Bizkaia, Unai Rementeria Maiz, in the presence of important authorities, including the Minister of Economic Development, Sustainability and Environment of the Basque Government, Arantxa Tapia, entrepreneurs, scientists, investors, managers and the company’s professional team, among other guests.
This is a pioneering company in the world whose unique technology places it at the forefront of one of the most innovation-intensive sectors. At the same time, it reinforces the Basque Country’s position as a world-class biotechnology hub.
“Our technology, which we call oDNATM – optimised and adaptable DNA – is unique in the world. Until now, nobody had managed to model the properties of DNA and optimise them for therapeutic applications. This has great advantages for both pharmaceutical companies and patients, as what used to take months can now be achieved in just weeks, is safer and specifically adapted to each need,” said Julen Oyarzabal, Chief Scientific Officer of Syngoi (CSO).
The company will produce for all phases of drug development, from early research, pre-clinical and clinical phases to large-scale production with cGMP quality.
Syngoi is uniquely positioned to be an optimal supplier to organisations that are leading the market for gene therapies, cell therapies and mRNA vaccines. These emerging therapeutic strategies have a manufacturing bottleneck that Syngoi’s oDNATM helps to solve.
The initial private investment has been in excess of €10M and is creating a pipeline of high-level direct jobs that will continue to grow throughout this year and beyond.
Syngoi is part of the portfolio of Columbus Venture Partners, a venture capital firm specialising in biotechnology, which has founded leading companies such as Viralgen, Vivet Therapeutics, Highlight Therapeutics and Aura, among others. This investment reinforces the fund manager’s commitment to the Basque Country as a world leader in the production of advanced therapies.
It is a significant boost for the sector and great news for patients, as they will have earlier access to effective specific treatments.
